BioSig has developed the PURE EP System, a next-generation electrophysiology (EP) information system, to improve cardiac signal recordings during ablation procedures. The document discusses the clinical need for better signal quality to optimize outcomes and efficiency. BioSig is validating the PURE EP System at leading cardiac centers and plans to submit an FDA 510(k) application in Q4 2015. The company has achieved key milestones on its development timeline and is supported by a proven management team and medical advisory board.

2. 2
This presentation forward-looking statements including statements that address activities, events or developments
that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial
performance, approvals and launches by BioSig of new products, market acceptance of BioSig’s products, market
and procedure projections, financing plans, and related documents. Forward-looking statements are based on
BioSig’s experience and perception of current conditions, trends, expected future developments and other factors
it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of
which are beyond BioSig’s control.
These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market
acceptance of products, BioSig’s ability to develop and market new and enhanced products, the timing of and
ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to
obtain such clearances and approvals on its ability to promote its products and train doctors in the use of its
products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig’s products and
the potential impact of current healthcare reform initiatives thereon, competition from existing and new products
and procedures or BioSig’s ability to effectively react to other risks and uncertainties described from time to time in
BioSig’s SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers,
litigation or other proceedings (including by the FDA), government regulation, negative publicity, current worldwide
economic conditions and share price volatility.
BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those
projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Disclaimer

3. 3
 Proven Management Team & Board of Directors
 World-Class Medical Advisory Board
 EP Devices: $3B Total Addressable Market, 12.1% CAGR
 Large Cardiac Arrhythmia Patient Population; Ablations Grow 10%+
 Increasing Demand for New EP Technologies to Address:
 Complex Ablation Treatments
 High Costs, with Higher Patient Throughput, Shorter Procedure Times
 Unacceptably High Recurrence Rates (31% - 46%)
 High-Growth Sector Earns Innovation Premium, Aggressive M&A
BioSig Investment Highlights

4. 4
Cardiac Arrhythmias
1 in 18 (14.4M) Americans Suffer
Increases individual’s risk of
Stroke 4- to 5-fold* - 5th Leading
Cause of Death in the US
 Most Common Arrhythmia:
U.S. = 2.7M 2010; 5.6M by 2050*
(7M - 12M Worldwide)
≈600,000 hospitalizations/year*
Direct cost = $6B annually;
adding other indirect costs brings
AF total cost to $26B*
 Ventricular tachycardia (VT) and
ventricular fibrillation (VF) are
rapidly fatal if not reversed
 Ventricular arrhythmias account
for >350,000 Sudden Cardiac
Deaths annually*
* American Heart Association data
ATRIAL FIBRILLATION (AF) VENTRICULAR TACHYCARDIA

5. 5
Cardiac EP: Large & Growing Market
 EP Labs: Estimated 4,000 WW; 2,800 in the U.S.
 In 2012: 260,000 U.S. catheter ablation procedures; 600,000 WW
 Average ablation procedure price (USD): $6,000 - $15,000
Sources: 1. Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019 2. HRI 2013 “Global Opportunities in
Medical Devices & Diagnostics” report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter
$2.5
$5.5
$-
$1.0
$2.0
$3.0
$4.0
$5.0
$6.0
2012 2019
EP Devices: 12.1% CAGR is One of the Fastest
Growing Cardio Medical Device Segments1
$ Billions
97,250
160,000
-
50,000
100,000
150,000
200,000
2012 2017
U.S. AF and VT Catheter Ablations2
Forecasted to grow 10.5% annually through 2017
(VT 13.9% CAGR and AF 10.1% CAGR)Current EP Market is ~$3B worldwide

6. 6
BioSig’s Technology Addresses Critical Issues
 High ablation recurrence rates: 31% for
paroxysmal AF; 46% for persistent/permanent AF
 Long procedure times: from 2-8 hours depending
on case, clinician experience
 Outdated technology: EP recording systems use
core technology from the 1990s
 Strong market demand for clear, accurate and
real-time diagnostic data
 Artifacts and noise generated by other EP lab
equipment may compromise signal quality
 Anti-arrhythmic drug therapies have limited
effectiveness, driving demand for catheter ablation

7. 7
PURE EP proof of concept system during
UCLA validation studies
PURE EP™ System
BioSig Technologies, Inc. has developed
a novel Electrophysiology (EP) information
platform – PURE EP™ System
The PURE EP System acquires and displays high
fidelity intracardiac (IC) & electrocardiogram (ECG)
signals.
PURE EP assists electrophysiologists in making
clinical decisions during cardiac catheter ablation in
real-time by providing information that we believe is
not always obtainable from any other equipment
presently used in EP labs.

8. 8
System dedicated to improving cardiac signal recordings - fundamental for
accurate diagnoses and treatments of cardiac arrhythmias
Preserves morphology of the patient’s cardiac signalsCLEAR ECG & IC
SIGNALS
Visualize crucial information in real-time
REAL-TIME
ANALYSIS
Aide in optimizing procedure time and decision makingIN ORDER TO
PURE EP™ System

9. 9
Electrograms & ECG signals – important for diagnoses and treatments
Inadequate signal quality may lead to poorer outcomes,
clinical and economic inefficiencies

PURE EP System is designed to preserve morphology of ECG & IC signals
to ensure optimal clinical decision making

Signals may become degraded by environmental noise and
signal processing
PURE EP System Value Proposition


10. 10
Current PURE EP System Prototype
PURE EP System Prototype connected to an ECG/IC Simulator

11. 11
PURE EP System Development to Date
 Jan 2009 - Jan 2011 – Research activities
 Understanding EP Lab environment/workflow and concepts of
“Electroanatomy” vs. “Electrophysiology”
 Defining architecture of the new system
 June 2011 – Visit to TCAI
 PURE EP System concept discussions w/Drs. Natale & Di Biase
 June 2013 – PURE EP System Proof of Concept (POC)
 Testing at UCLA’s EP & Animal Labs
 September 2014 – PURE EP System Prototype
 Test at UCLA Animal Lab
 December 2014 – Visit to Mayo Clinic
 PURE EP System presentation and planning Animal Studies with Drs.
Asirvatham and Venkatachalam
 March 2015 – Animal Study at Mayo Clinic

12. 12
Validation of PURE EP System
 Testing of the PURE EP System is underway
in EP and animal labs at UCLA and Mayo
Clinic
 BioSig is collaborating with leading
Cardiac Centers:
 Texas Cardiac Arrhythmia Institute
 UCLA Cardiac Arrhythmia Center
 U.H. Case Medical Center in Cleveland
 William Beaumont Hospital in Michigan
 Mount Sinai Medical Center in NY
 Mayo Clinic in Minnesota
 BioSig has developed an ECG/IC simulator
to objectively measure/compare PURE EP’s
performance vs. existing EP systems
PURE EP proof of concept system during
UCLA validation studies

13. 13
World-Class Scientific Advisory Board
Leading authorities in electrophysiology
Andrea Natale, MD, Chairman Executive Medical Director, Texas Cardiac Arrhythmia Institute, St. David’s Medical Center
Samuel Asirvatham, MD
Professor of Medicine & Vice Chair of Division of Cardiovascular Diseases, Department of Medicine;
program director Clinical Cardiac Electrophysiology Training Program, Mayo Clinic in Rochester,
Minnesota
K. L. Venkatachalam, MD
Assistant Professor of Medicine, Division of Cardiovascular Diseases, Mayo Clinic in Jacksonville,
Florida
Kalyanam Shivkumar, MD, PhD Director, UCLA Cardiac Arrhythmia Center; Professor of Medicine & Radiology
Mauricio Arruda, MD Director, Clinical Electrophysiology & Pacing, University Hospitals Case Medical Center
Vivek Reddy, MD
Director, Cardiac Arrhythmia Service and a Helmsley Trust Professor of Medicine, Mount Sinai
Medical Center in New York
Luigi Di Biase, MD, PhD
Senior Researcher at Texas Cardiac Arrhythmia Institute; Associate Professor, Albert Einstein College
of Medicine, Adjunct Professor at the UT Austin

14. 14
EP Market: Intense Competition & Rapid Technological Advances
 4 large companies share the majority of EP recording market share
 They produce the following EP recording systems @~$250,000/unit:
 Bard’s LabSystem PRO EP Recording System, originally designed in the late
1980s; acquired by Boston Scientific in 2013
 Siemens developed the Axiom Sensis XP in 2002
 GE’s CardioLab Recording System developed early ‘90s by Prucka Engineering;
acquired by GE 1999
 St. Jude Medical’s EP-WorkMate Recording System was acquired from EP
MedSystems in 2008, received FDA approval in 2003
EP Competitive Landscape

15. 15
EP Sector M&A Activity
Company
Proofof
Concept
Prototype
Clinical
Data
CEMark
FDA
Sales
Acquirer/
Investor Valuation
Abbott/Topera
(Closing Q4-14 )
• • • • • Abbott
$250M+ milestone $$
Q4-14 Deal
Bard EP
Division of CR Bard • • • • • • Boston Scientific
$275M
2013 Deal
Rhythmia Medical
Formed 2004 • • • Boston Scientific
$265M
2012 Deal
Ablation Frontiers
Formed 2004 • • • • Medtronic
$225M+
2009 Deal
EP Medsystems
Formed 1993 • • • • • St. Jude
$92.1M
2008 Deal
Cryocath
Formed 1995 • • • • • Medtronic
$380M
2008 Deal
Endocardial Solutions
Formed 1992 • • • St. Jude
$272M
2005 Deal
Prucka Engineering
Formed 1988 • • • • • GE
Undisclosed
1999
BioSig Technologies
Formed 2009 • • •

16. 16
Proven Management Team & Board
Gregory D. Cash
President, CEO and Director
Former Pres: Argent International, NeuroTherm, Heartsine Tech, Vasomedical, Datascope, Eminent Tech; Mgmt: U.S. Surgical,
Boston Scientific, Medtronic
Kenneth L. Londoner, MBA
Co-Founder, Executive Chairman/Director
Principal: Endicott Mgmt Partners, J & W Seligman & Co; Director: Alliqua, Red Coat Capital Management
Steve Chaussy, CPA
Chief Financial Officer
CFO; Liberski Inc, Anna & Co, Penske Truck Leasing, Ford Hogg and Cobbe
Jay O. Millerhagen, MS, MBA
VP, Clinical Research
VP Clinical/Mkt Dev: RESPICARDIA, Inc.; VP/Sr Dir Clinical: St Jude Medical; Dir New Product Planning, Brady Mktg, Heart Failure
R&D/Mktg, Bus Alliance Mktg with J&J, GE Healthcare: Boston Scientific
Brian McLaughlin
VP Corporate Finance, Investor Relations
President & COO: Ridgeback Capital,; Head of Trading: Sigma Capital; Front Office Capital Market Positions: SAC Capital & the
investment bank, JP Morgan & Co.
Michele Chin-Purcell, PhD
VP Quality & Regulatory Affairs
Sr. Dir RA: Spinal Modulation; Sr. Dir RA: St Jude Medical: Guidant/Boston Scientific: QA/RA/Compliance
Outside Directors:
Roy T. Tanaka
Former Pres: J&J; Dir: TomoTherapy, Volcano Corp, Advanced Cardiac Therapeutics, VytronUS, Coherex Medical
Jerome B. Zeldis, MD, PhD Current CEO of Celgene Global Health & Chief Medical Officer of Celgene Corporation
Asher Holzer, PhD Founder: InspireMD; Mgr: CARTO System, Biosense
Jonathan Steinhouse VP Sales: Oracle, Sandlot Solutions, Orange MZI Healthcare currently
Patrick J. Gallagher Mg Dir: Laidlaw; Kinex Pharma; Dir: Cingulate Therapeutics, BDR Research Group, GC Capital Partners, Kidder Peabody
Jeffrey F. O’Donnell, Sr.
Current CEO, Chair: Trice Medical; Current Chair: Mela Sciences; Founder: Embrella Cardiovascular (sold to Edwards Lifesciences); CEO:
PhotoMedex, Radiance Medical (Cardiovascular Dynamics), Kensey Nash; Sales/Mktg Mngt: Boston Scientific, Guidant, J&J; Former Director:
Cardiac Science, Endologix
Seth H. Z. Fischer Current CEO & Dir: Vivus, Inc; Former WW Chairman: J&J, Cardiovascular

17. 17
 Animal Studies at Mayo Clinic and UCLA Cardiac Arrhythmia Center
 Commence Additional Research Studies
 Submit FDA 510(k) Application Q4-15
 Continue to Build Intellectual Property Portfolio
 Uplist to National Exchange in 2015
 Prepare for Commercialization
BioSig’s Key 12-Month Milestones

18. 18
Milestones & Timelines

19. 19
Financing History
Founders: 2009-2010
Friends & Family: Mar 2011 $150K $7M PMV*
Series A Preferred: June 2011 $1M $15M PMV
Series B Preferred: April 2012 $1M $17.5M PMV
Series C Preferred: July 2013 $2.78M $20M PMV
Common: April 2014 $1.37M $36 - $38M PMV
Common: Sept 2014 $1M $51M PMV
Common: Mar 2015 $4M $60M PMV
 No Debt
 Consistent Management & Board Participation in Financings
*PMV = Pre-Money Valuation

20. 20
 Proven Management Team & Board of Directors
 World-Class Medical Advisory Board
 EP Devices: $3B Total Addressable Market, 12.1% CAGR
 Large Cardiac Arrhythmia Patient Population; Ablations Grow 10%+
 Increasing Demand for New EP Technologies to Address:
 Complex Ablation Treatments
 High Costs, with Higher Patient Throughput, Shorter Procedure Times
 Unacceptably High Recurrence Rates (31% - 46%)
 High-Growth Sector Earns Innovation Premium, Aggressive M&A
BioSig Investment Highlights

21. 21
Gregory Cash
President & Chief Executive Officer
(612) 309-4747
gcash@biosigtech.com
Ken Londoner
Co-Founder, Executive Chairman
(203) 644-5200
klondoner@biosigtech.com
Brian McLaughlin
VP, Corporate Finance & Investor Relations
(917) 370-9817
bmclaughlin@biosigtech.com
This document is being provided on a confidential basis by BioSig Technologies, Inc. solely for the information of those persons to whom it is transmitted. No person in any jurisdiction may treat this
document as constituting either an offer to sell or solicitation of an offer to buy any securities in the Company. A prospective subscriber must rely solely on the terms of and disclosure of information
including important information regarding risks and conflicts of interest contained in the Company's final offering memorandum and related documents, the only basis on which subscriptions may be made.
Contact BioSig

22. 22
PURE EP proof of concept system during
UCLA validation studies.
BioSig Technologies Profile
BioSig Technologies, Inc. has developed
a next-generation Electrophysiology (EP)
Information System – PURE EP™ System.
The PURE EP System acquires and displays high
fidelity intracardiac (IC) & electrocardiogram (ECG)
signals.
PURE EP assists electrophysiologists in making
clinical decisions during cardiac catheter ablation in
real-time by providing information that BioSig
believes is not always obtainable from any other
equipment presently used in EP labs.

23. 23
Why are EP Signals Critical?
Quality Cardiac Signal Recordings ⇒
Assist in Better Clinical Decision Making
 Strong demand for clear, accurate and real-
time diagnostic data
 Signal noise in EP labs may lead to inefficient
procedures
 Certain arrhythmia ablation procedures
currently performed by only limited number of
centers due to complexities
During EP procedures, catheters are placed on
cardiac tissue to record signals and apply energy to
destroy abnormal electrical pathways